Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004865 · ClinicalTrials.gov registry record · Phase 2
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004865: Completed Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00004865 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004865, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating patients who have metastatic or recurrent cancer of the head and neck that has not responded to previous cisplatin-based chemotherapy.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG fluorouracil
- BIOLOGICAL cetuximab
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Phase | Phase 2 |
What the finished NCT00004865 record still lists
NCT00004865 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00004865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004865 about?
NCT00004865 is a clinical study titled "Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy". RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal a...
What is the current status of trial NCT00004865?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-11.
What interventions are being tested in trial NCT00004865?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), fluorouracil (DRUG), cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004865?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia